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Open Forum Infectious Diseases
REVIEW ARTICLE (INVITED)

Adriana M. Rauseo,1 Ariella Coler-Reilly,2 Lindsey Larson,1 and Andrej Spec1,
1
Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA, 2Washington University School of Medicine, St. Louis, Missouri,
USA

The treatment of invasive fungal infections remains challenging due to limitations in currently available antifungal therapies including toxicity, interactions, restricted routes of administration, and drug resistance. This review focuses on novel therapies in clinical development, including drugs and a device. These drugs have novel mechanisms of action to overcome resistance, and some offer
new formulations providing distinct advantages over current therapies to improve safety profiles and reduce interactions. Among
agents that target the cell wall, 2 glucan synthesis inhibitors are discussed (rezafungin and ibrexafungerp), as well as fosmanogepix
and nikkomycin Z. Agents that target the cell membrane include 3 fourth-generation azoles, oral encochleated amphotericin B, and
aureobasidin A. Among agents with intracellular targets, we will review olorofim, VL-2397, T-2307, AR-12, and MGCD290. In addition, we will describe neurapheresis, a device used as adjunctive therapy for cryptococcosis. With a field full of novel treatments for
fungal infections, the future looks promising.
Keywords. antifungal drugs; invasive fungal infections; novel treatment; review.
Fungal infections are among the most difficult diseases to
manage in humans, with approximately 1.7 billion individuals suffering from these infections worldwide [1, 2]. Invasive
fungal infections (IFIs) refer to systemic fungal infections, in
which fungi have infiltrated and established themselves in the
deep tissues, resulting in life-threatening illness [3]. Although
IFIs have a lower incidence compared with superficial fungal
infections, they carry substantial human morbidity, mortality,
and economic burden [1, 2, 4]. The overall mortality in patients with IFIs is as high as 45% [5]. These mortality rates
remain high, and they often exceed deaths due to tuberculosis
[6, 7] and malaria, despite the availability of several effective
antifungal drugs [1, 2, 4].
More than 90% of all reported fungal-related deaths result
from Cryptococcus, Candida, Aspergillus, Histoplasma, and
Pneumocystis [2, 7]. Other emerging opportunistic fungal
pathogens, including molds such as Fusarium spp, Scedosporium
spp, Penicillium spp, Lomentospora spp, and the Mucorales, are
becoming significantly more prevalent due to selective pressure
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from use of antifungals in agriculture, prophylaxis, and empirical therapy [8–10]. There has recently been a rise in resistant
species and isolates, such as Candida auris, azole-resistant
Aspergillus spp, and Lomentospora (previously Scedosporium)
prolificans, some of which are resistant to all currently available
antifungals [11–13].
Great strides were made in the 1990s after the introduction
of second-generation azoles, echinocandins, and lipid formulations of amphotericin B (AmB), but drug development
has largely stalled since then [1]. Currently, 3 main classes of
antifungals are approved for the treatment of IFIs: polyenes,
azoles, and echinocandins [14]. These agents target ergosterol in the cell membrane, lanosterol 14α-demethylase, and
1,3-β-glucan synthase, respectively [14]. The newest class of
antifungal drugs, the echinocandins, was discovered in the 1970s
and took almost 30 years to be approved. The first echinocandin,
caspofungin, gained approval in 2001, representing the only
novel class of antifungals to be approved in the 21st century
[15]. Only 1 antifungal drug (isavuconazole) has been approved
and marketed over the last decade [16]. Compared with the development of new antibacterials, antifungal drug development
is hampered because fungal pathogens are very closely related
to humans, using the same eukaryotic machinery, and therefore offer few pathogen-specific targets [5, 17]. New antifungal
therapies that act through novel mechanisms are needed to reduce the high mortality of invasive fungal disease and combat
the emergence of resistance to existing therapies. However,
with several promising drugs in development, the future looks
bright. This review focuses on novel therapies in the pipeline at
various phases of clinical development.
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Hope on the Horizon: Novel Fungal Treatments in
Development

THE NOVEL THERAPEUTICS
AGENTS TARGETING CELL WALL INTEGRITY
Rezafungin (CD101)

Mechanism of action and potential role.

Pharmacokinetics/Pharmacodynamics

Pharmacologically, rezafungin has a much longer half-life (approximately 80 hours after the first dose and 150 hours after the
second or third dose) than any currently available echinocandin,
allowing for extended-interval IV dosing, such as weekly regimens [21]. Theoretically, this would increase pathogen killing
and reduce spontaneous mutations by maximizing the drug effect early in the course of therapy when the burden of the pathogen is greatest [21, 25].
Evidence supports the use of weekly dosing for the treatment of patients with candidemia and invasive candidiasis,
and higher doses might be able to overcome FKS mutant
Candida isolates [26]. To evaluate the potential for resistance
to rezafungin in Candida spp, spontaneous mutations to the
drug were compared with caspofungin and anidulafungin, and
results indicated an overall low potential for resistance development. Rezafungin has the additional advantage of higher
plasma drug exposure due to the front-loaded dosing regimen,
which further lowers the risk of resistance development [27].
However, the risk of development of resistance in the long “tail”
of the pharmacokinetics (PK) has yet to be fully evaluated.
Activity

Rezafungin exhibits a broad in vitro potency against fungal pathogens comparable to that of other echinocandins [20, 25, 28, 29]
(Figure 2). Rezafungin has concentration-dependent fungicidal activity and is highly bound to plasma proteins with extensive tissue
distribution and minimal urinary excretion [21, 22, 30]. Rezafungin
2 • ofid • Rauseo et al

Stage of Development and Ongoing Clinical Studies

A phase 1 study showed low toxicity and a favorable safety profile in humans with no serious or severe adverse events (AEs) or
withdrawals from the study due to an AE, with the majority of
AEs being mild and all with complete resolution [21]. Studies
showed no biotransformation in liver microsomes or hepatocytes, reducing the risk of hepatotoxicity, and minimal inhibition
of cytochrome P450 (CYP450) enzymes [21, 22]. Rezafungin,
compared with conventional echinocandins, displays improved
drug penetration for intra-abdominal candidiasis (IAC) [36].
In a phase 2 multicenter, randomized, double-blinded trial
(STRIVE trial, NCT02734862), patients with candidemia and/or
invasive candidiasis receiving rezafungin were compared with patients receiving a regimen of daily caspofungin with fluconazole
stepdown once clinically stable. Rezafungin was well tolerated
and provided clearance of blood cultures and other sterile sites,
meeting all primary safety and efficacy end points [37]. Currently,
patients are being recruited for a phase 3 study (ReSTORE study,
NCT03667690) to determine the noninferiority of rezafungin
compared with caspofungin in treatment of candidemia and/or
invasive candidiasis, with the primary outcome being all-cause
mortality at day 30. Future plans include a second phase 3 trial
(ReSPECT study) using rezafungin in a 90-day prophylactic
regimen for Candida, Aspergillus, and Pneumocystis infections
in allogeneic bone marrow transplant patients, with results expected in 2020 (Figure 3). Unfavorable results from a phase 2
trial (RADIANT study, NCT02733432) investigating topical
rezafungin (gel and ointment) resulted in the withdrawal of the
topical formulation for the potential treatment of vulvovaginal
candidiasis (VVC) [38, 39].
Ibrexafungerp (SCY-078)

Mechanism of Action and Potential Role

Ibrexafungerp (previously MK-3118 and SCY-078; developed by
Scynexis, Jersey City, NJ) is a first-in-class oral glucan synthase
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Rezafungin (formerly SP3025 and CD101; developed by Cidara
Therapeutics, San Diego, CA) is a novel echinocandin, currently in
phase 3 development for treatment of candidemia and invasive candidiasis, with pharmacokinetic and safety qualities that distinguish
it as a next-generation echinocandin [18–21]. Studies have also
shown potential use for prevention of infections caused by Candida,
Aspergillus, and Pneumocystis spp in bone marrow transplant patients, with a prophylaxis trial in planning [22, 23]. The US Food
and Drug Administration (FDA) has designated intravenous (IV)
rezafungin as a Qualified Infectious Disease Product (QIDP) with
fast track status for its development program.
Rezafungin is a structural analog of anidulafungin with a
modified choline moiety at the cyclic echinocandin core for
greater chemical and metabolic stability and solubility. This
might prevent hepatotoxicity by decreasing secondary metabolites [18] while retaining the antifungal activity of an
echinocandin by inhibition of β-1,3-glucan synthesis [22]
(Figure 1 and Table 1).

is being developed as a subcutaneous and IV medication [18, 31].
Previous in vivo pharmacodynamics studies demonstrated robust
efficacy against Candida spp, including multidrug-resistant isolates
such as C auris [32–34] and Aspergillus spp [35]. By both Clinical
and Laboratory Standards Institute (CLSI) and EUCAST broth
microdilution methods, the minimum inhibitory concentrations
(MICs) for rezafungin were determined to range between ≤0.008
and 2 mg/L against Candida albicans, Candida glabrata, Candida
tropicalis, Candida dubliniensis, and Candida krusei and between
0.5 and 2 mg/L against Candida parapsilosis [20]. Activity against
Aspergillus spp, including Aspergillus fumigatus, Aspergillus terreus,
Aspergillus flavus, and Aspergillus niger isolates, was comparable
to other echinocandins with minimal effective concentrations
(MECs) that ranged from ≤0.008 to 0.03 mg/L in one study [20]
and ≤0.015–2 mg/L for all Aspergillus isolates, including azoleresistant isolates in another study [29].
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Figure 1. Mechanism of action and target sites of the novel antifungals. The antifungal compounds currently in development have several novel mechanisms of action or
new formulations to (1) improve efficacy or reduce toxicity and (2) target different sites in the cell wall, cell membrane, and also intracellular targets. DHODH, dihydroorotate
dehydrogenase; IPC, inositol phosphorylceramide.

inhibitor, semisynthetic derivative of enfumafungin and represents the first compound of the triterpenoid antifungals to
reach clinical development for the treatment of invasive candidiasis [40]. Although structurally different from echinocandins,
it has the same fungal target through inhibition of β-1,3-glucan
synthase [41] (Figure 1 and Table 1). Ibrexafungerp has been
designated as a QIDP for oral and IV use by the FDA, for the
indications of invasive candidiasis and invasive aspergillosis.
Pharmacokinetics/Pharmacodynamics

Ibrexafungerp is being developed for both oral and IV dosing,
but only the oral dosing is currently in clinical trials [41]. It is
characterized by high-volume distribution and extensive tissue
penetration. It met efficacy end points across multiple murine models of invasive candidiasis at concentrations that have
been safely achieved after oral administration in humans, but
it does not achieve central nervous system (CNS) penetration
[16, 40]. Despite binding to plasma proteins, the affinity may be
weak, thereby allowing distribution to tissues [40]. An in vitro
study showed robust drug penetration at the site of infection

for IAC. Drug concentrations within the necrotic center of liver
abscesses are almost 100-fold higher than the serum concentrations at corresponding time points [42]. Ibrexafungerp exhibits
pH-dependent solubility, achieving the highest concentrations
in acidic media consistent with simulated gastric and intestinal
fluids, which may increase its efficacy in vaginal tissues as well
as in abscesses [40]. Orally administered ibrexafungerp accumulates in the acidic environment of vaginal tissue in mice [43].
In vitro studies indicate that ibrexafungerp is a modest inhibitor
of CYP450 (CYP2C8) with markedly lower effect over other
CYP450 isozymes; however, substrates were not affected to a
clinically meaningful extent in the presence of therapeutically
relevant ibrexafungerp concentrations, suggesting low risk for
significant CYP450 drug-drug interactions [44, 45].
Activity

In vitro and in vivo studies have demonstrated potency against
the most common Candida spp, as well as resistant isolates [41,
46–51]. In addition, it demonstrates excellent in vitro activity
against wild-type and azole-resistant strains of Aspergillus spp,
Novel Fungal Treatments • ofid • 3
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Glucan synthesis inhibitors

Expected Benefits

• Minimal DDI (selective for fungal
CYP51 enzyme)
• Broad spectrum
• Longer half-life

Candida spp (including C auris),
Aspergillus spp, Coccidioides,
Blastomyces, Histoplasma, R arrhizus

VT-1129

VT-1598

Oral and IV formulation
Active against resistant strains
Better penetration (IAC)
Minimal drug-drug interactions

• Minimal DDI (selective for fungal
CYP51 enzyme)

•
•
•
•

Candida spp, Coccidioides immitis/C
posadasii, Trichophyton spp, Rhizopus
arrhizus var. arrhizus

Candida spp (including C auris),
Aspergillus spp Paecilomyces variotii,
Lomentospora prolificans, Pneumocystis spp
Lacks activity: Mucor and Fusarium spp

Candida spp (including Candida auris),
• Not hepatotoxic
Aspergillus spp, and Pneumocystis spp • Longer half-life (weekly dosing)
• Better penetration (IAC)
• Less risk of resistance
• Active against resistant strains
• SQ and IV formulation
• Better adherence, less hospital costs

Spectrum of Activity

VT-1161 (Oteseconazole)

Inhibition of β-1,3-glucan
synthesis

Mechanism of Action

• Minimal DDI (selective for fungal
CYP51 enzyme)
• Oral formulation

Chemical Structure

Inhibition of lanosterol
Cryptococcus neoformans/C gatti, Can14α-demethylase (CYP51) dida spp

Ibrexafungerp (SCY078)

Novel Therapy

Novel Antifungals With Chemical Structure, Mechanism of Action, Spectrum of Activity, Expected Benefits

Class

Table 1.
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Novel Therapy

MAT2203 (CAmB)

Olorofim (F901318)

Fosmanogepix (APX001)

Class

Polyenes

Orotomides

Glycosylphosphatidylinositol (GPI)
inhibitors

Chemical Structure
Candida spp, Aspergillus spp,
Cryptococcus spp

Ergosterol binding, pore
formation in the fungal
membrane
• Oral formulation
• Less toxicity
• Minimal DDI

Expected Benefits

Inhibition of Gwt1, GPICandida spp (including C auris), C
anchor protein synthesis
neoformans, C immitis, Aspergillus
spp, Fusarium, Mucorales,
Lomentospora
Lacks activity: Candida krusei

• Less toxicity (fungal specific target)
• Broad spectrum, active against resistant isolate

Inhibition of fungal DHODH,Aspergillus spp, Histoplasma,
• Oral formulation
pyrimidine synthesis
Blastomyces, C immitis, Taloromyces • Active against pan-resistant fungi
marneffei, Fusarium spp, L prolificans, • Less toxicity (fungal specific target)
Scopulariopsis brumptii
Lacks activity: Candida spp, Cryptococcus
spp and Mucorales

Spectrum of Activity

Mechanism of Action
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Novel Therapy

Nikkomycin Z

T-2307

VL-2397 (ASP2397)

AR-12

Chitin synthases inhibitors

Arylamidine

Siderophore

Anticancer protein kinase inhibitor

Continued

Class

Table 1.
Chemical Structure

Candida spp, C neoformans/C gattii,
• Clinically safer than pentamidine
Malassezia furfur, Aspergillus spp and • Preferential uptake by fungal cells
Fusarium solani

Unknown, possible mitochondrial collapse

Inhibition of fungal acetylCoA synthetase

Candida spp, C neoformans,
Blastomyces, Histoplasma,
Coccidioides, Fusarium, Mucor,
Lomenstospora, Trichophyton rubrum

• Repurposed antifungal agent

Unknown intracellular
Aspergillus spp, C glabrata, Candida kefyr,• Selective fungal target
target, uptake via specific C neoformans, and Trichosporon asahii • Activity against azole-resistant isolates
siderophore iron trans- Lacks activity: Aspergillus niger,
porter (Sit1)
other Candida spp, Mucorales,
Scedosporium apiospermum, and
Fonsecaea pedrosoi

• Synergistic effect with echinocandins
• Orphan drug for coccidioidomycosis

C immitis, Histoplasma capsulatum,
Blastomyces dermatitidis
Adding echinocandins: Candida spp,
Aspergillus spp
Lacks activity: Aspergillus spp

Inhibition of chitin synthases

Expected Benefits

Spectrum of Activity

Mechanism of Action
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MGCD290

Neurapheresis

Histone deacetylase
inhibitors

Device

N/A

Structure not disclosed [24]

Chemical Structure

Spectrum of Activity
• Less toxicity
• Broad spectrum

Expected Benefits

Extracts contaminated CSF Cryptococcal meningitis
through filtration system

•
•
•
•

Adjunctive therapy for CM
Decrease risk of hydrocephalus
Allows to modulate high ICP
Minimize repeat LP and shunt placement

Inhibition of fungal histone Candida spp, Aspergillus spp, Mucor and • Synergistic effect with azoles and
deacetylase (Hos2) and
Fusarium (in combination with azole/
echinocandins
nonhistone proteins
echinocandin)
• Decreases MICs in resistant isolates
(Hsp90)

Inhibition of inositol
Saccharomyces cerevisiae, Canphosphorylceramide (IPC) dida spp, Cryptococcus spp,
synthase, sphingolipid
Schizosaccharomyces pombe
syntheses

Mechanism of Action

Abbreviations: CAmB, encochleated amphotericin B; CM, cryptococcal meningitis; CSF, cerebrospinal fluid; DDI, drug-drug interactions; IAC, intra-abdominal candidiasis; ICP, intracranial pressure; IV, intravenous; LP, lumbar puncture; MIC, minimum inhibitory concentration; N/A, not applicable; SQ, subcutaneous.

Novel Therapy

Aureobasidin A

Class

Continued

Glycolipid inhibitors

Table 1.
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Figure 2. Novel antifungals with spectrum of activity. New antifungal compounds show extensive spectrum of activity to overcome resistant fungi; however, several
gaps still remain. *MGCD290: Potent activity in combination with azoles and/or echinocandins. ABA, aureobasidin A; CAMB, encochleated amphotericin B; FOSMANO,
fosmanogepix; GSI, glucan synthase inhibitor; IBREXA, ibrexafungerp; NIKZ, nikkomycin Z; REZA, rezafungin.

Paecilomyces variotii, and some activity against L prolificans,
but poor activity was observed against Mucor and Fusarium
spp [47, 52]. It retains activity against Candida FKS1 or FKS2
mutants [53], including echinocandin-resistant isolates of C
glabrata and C auris [41, 46–51]. Due to differential binding
sites, the FKS mutations associated with echinocandin resistance are distinctly different from those reducing susceptibility
to the enfumafungin derivatives including ibrexafungerp, limiting cross-resistance [47]. By both CLSI and EUCAST broth
microdilution methodologies, MICs were determined to be
0.06–2 mg/L against C albicans and C tropicalis, 0.25–1 mg/L
against C parapsilosis, and 0.5–2 mg/L against C glabrata and
C krusei [46]. Against Aspergillus spp, MEC values reported
were 0.03–1 mg/L and 0.015–0.25 mg/L when tested by CLSI
and EUCAST methods, respectively [47]. Studies also show
that oral ibrexafungerp could be a viable option for managing
Pneumocystis in immunocompromised patients, because it has
shown significant activity in a murine therapy and prophylaxis
model [54, 55] (Figure 2).
Stage of Development and Ongoing Clinical Studies

Ibrexafungerp met primary end points in 2 phase 2 clinical
trials (NCT02679456, NCT02244606) in VVC and invasive
candidiasis, respectively. In VVC, oral ibrexafungerp was superior compared with oral fluconazole (78% vs 65%), and at
8 • ofid • Rauseo et al

the end of a 4-month follow-up period (88% vs 65%) with a
lower recurrence rate (4% vs 15%) [56]. For invasive candidiasis, ibrexafungerp, as an oral step-down treatment after 3–10
days of echinocandin therapy, compared with fluconazole,
achieved the predetermined target exposure in most subjects
[57]. Mild-to-moderate gastrointestinal events such as diarrhea,
nausea, vomiting, abdominal pain or discomfort were seen with
ibrexafungerp, but no discontinuations due to AEs or serious
AEs were observed. No mycological failure was reported in the
study drug arm [57]. A recently completed phase 2 trial, the
DOVE study (NCT03253094), explored 5 dosing regimens of
oral ibrexafungerp versus fluconazole in patients with acute
VVC to identify an optimal dose for a phase 3 trial. Results have
not been published.
Currently, there are multiple ongoing phase 3 trials [58]
(Figure 3). The CARES study (NCT03363841), open for enrollment in the United States and India, is assessing ibrexafungerp
for the treatment of C auris infections. Initial evidence of efficacy
and safety in 2 subjects was presented with promising results [59].
The FURI study (NCT03059992) is evaluating the efficacy and
safety in patients with an invasive and/or severe fungal disease
that are refractory or intolerant to standard-of-care antifungal
treatment. Initial results of 20 patients who completed therapy
were favorable [60]. The Data Review Committee adjudicated
55% of patients as achieving complete or partial response, 30%
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Figure 3. Stage of clinical development of the novel antifungals. New antifungal compounds are currently in several stages of development. Most have advanced to phase 2 or 3, but a
few still remain in phase 1 or preclinical development. VL-2397 had early termination of phase 2 trial, and there are currently no ongoing trials. AR-12 and MGCD290 have no ongoing trials.

maintaining stable disease, 10% with progression of disease, and
1 case was considered as indeterminate [60]. Outcomes for 2
cases of C albicans and C tropicalis spondylodiscitis have shown
clinical data for its use in bone infections [61]. Upcoming studies
will evaluate oral ibrexafungerp in patients with acute VVC
(VANISH306 study, NCT03987620) and as combination therapy
with voriconazole in patients with invasive pulmonary aspergillosis (SCYNERGIA study, NCT03672292).
Fosmanogepix (APX001)

Mechanism of Action and Potential Role

Fosmanogepix (also known as APX001) (synthetized by Amplyx
Pharmaceuticals, San Diego, CA), a first-in-class antifungal, is
a prodrug of Manogepix (E1210), and it displays highly selective antifungal activity by inhibiting fungal enzyme Gwt1 and
subsequently inactivating posttranslational modification of
glycosylphosphatidylinositol (GPI) anchor proteins, also known
as mannoproteins [62]. The GPI-anchored proteins become covalently linked to β-1,3-glucan, helping maintain the integrity of the
fungal cell wall and play a role in adherence and invasion of host tissues. After GPI-anchor synthesis is disrupted, β-1,3-glucan can be
exposed, increasing recognition of the fungus by immune cells [63].
The action of fosmanogepix appears to be specific to fungi, because
it does not inhibit human inositol acylation, resulting in a wide therapeutic index [63] (Figure 1 and Table 1). Fosmanogepix received
QIDP and fast track designations as well as orphan drug status for

4 indications: invasive candidiasis, invasive aspergillosis, coccidioidomycosis, and rare molds, including Scedosporium and Fusarium.
Activity

Fosmanogepix has in vitro activity against a broad spectrum of
fungi, including yeast such as Candida spp [62–64], Cryptococcus
neoformans [65], Coccidioides immitis [66], and C auris [67, 68],
but it lacks activity against C krusei [62, 69], and it also has activity against many molds, including Aspergillus (even non-A
fumigatus spp), Fusarium, Mucorales, and Scedosporium spp
(including L prolificans) [62, 70, 71] (Figure 2). This drug has
also shown efficacy in animal models of IFIs, including candidiasis caused by azole and echinocandin-resistant isolates, aspergillosis, and fusariosis [72–75]. Animal models in both rats and
monkeys indicate that fosmanogepix is extensively distributed
to major tissues relevant to IFIs (including liver, lung, brain, and
eye) and cleared primarily by biliary and fecal excretion [76].
Stage of Development and Ongoing Clinical Studies

Phase 1 clinical studies have demonstrated >90% bioavailability
for fosmanogepix, in both oral and IV formulations. These trials
(NCT02957929, NCT02956499, NCT03333005) have determined the safety, tolerability, and PK of fosmanogepix in healthy
volunteers and patients with acute myelogenous leukemia, who
are at increased risk of IFIs. The clinical pharmacological profile, including drug-drug interactions and drug distribution,
was also studied [77, 78]. Currently, phase 2 proof-of-concept
Novel Fungal Treatments • ofid • 9
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Fosmanogepix (APX001)

studies are being conducted in patients with invasive candidiasis/candidemia and invasive aspergillosis [79] (Figure 3).
Nikkomycin Z

Mechanism of Action and Potential Role

Activity

Nikkomycin Z has potent in vitro and in vivo activity against dimorphic fungi with high quantities of chitin, including C immitis
and Blastomyces dermatitidis. This agent has demonstrated activity
in murine models of coccidioidomycosis, blastomycosis, and histoplasmosis [81–84]. Its fungicidal effect exceeded that of azoles and
AmB, by sterilizing the lungs of most mice in murine models of pulmonary coccidioidomycosis and blastomycosis; however, moderate
efficacy was seen for histoplasmosis [83, 85]. As monotherapy, it has
limited activity against some yeasts, such as C albicans, and no activity against filamentous fungi, such as Aspergillus [83]. Despite its
narrow spectrum, it has the potential to enhance other antifungal
treatments when combined with other drugs. For example, NikZ
in combination with echinocandins produced a synergistic effect
against A fumigatus [86, 87], and it has also been productive in combination with fluconazole and itraconazole for different Candida
and Aspergillus species [88] (Figure 2).
Pharmacokinetics/Pharmacodynamics

Pharmacologic studies in mice showed that NikZ administered
through IV infusion was rapidly eliminated; however, oral administration resulted in slow absorption, allowing inhibitory
levels to persist for hours [83]. Experimental murine studies
suggest that twice-daily dosing of 250–500 mg could achieve
optimal plasma concentrations in humans [89].
Stage of Development and Clinical Studies

Nikkomycin Z has completed phase 1 clinical development
(NCT00834184) and showed excellent safety in healthy humans,
without AEs observed [90]. A phase 2 trial (NCT00614666) to
determine a safe dose in patients with pulmonary coccidioidomycosis was terminated early due to recruitment challenges and
lack of funding [91, 92], but a phase 2a trial is planned for 2020
(Figure 3).
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VT-1129, VT-1161, and VT-1598

Mechanism of Action and Potential Role

One of the main limitations of the azole class of antifungals is
the clinically significant drug-drug interactions experienced
due to inhibition of off-target CYP450 [93]. VT-1129, VT-1161
(or Oteseconazole), and VT-1598 (developed by Viamet
Pharmaceuticals, Durham, NC) are next-generation azoles,
termed tetrazoles, attempting to remedy this limitation through
improved binding discrimination between fungal and mammalian CYP450 enzymes. By replacing the triazole metal-binding
group with a tetrazole, this group achieves greater selectivity for
fungal lanosterol 14α demethylase (CYP51) [94, 95], which will
hopefully result in fewer safety issues and lower MICs (Figure 1
and Table 1). The inhibition of this enzyme prevents conversion
of lanosterol to ergosterol, an essential component of the fungal
membrane. The FDA has granted QIDP, fast track, and orphan
drug designation to VT-1598 for the treatment of coccidioidomycosis, and VT-1161 received QIDP and fast track status for
recurrent VVC.
Activity

Each of these agents has potent activity against various yeast
isolates, including C albicans and non-C albicans species, and
Cryptococcus spp, as well as significant mold activity, including
the Mucorales (Figure 2).
Potent in vitro activity has been reported for VT-1161 against
Candida spp (MIC range, ≤0.03–0.25 mg/L), including wildtype isolates and some azole- and echinocandin-resistant strains,
C immitis/Coccidioides posadasii (1–4 mg/L), Trichophyton
spp (≤0.03–0.06 mg/L) [96–99], and against molds such as
Rhizopus arrhizus var. arrhizus [100]. In vitro activity against
Candida species has translated into in vivo efficacy in various
animal models, including those of VVC and invasive candidiasis secondary to wild-type, azole- and echinocandin-resistant
C albicans [101]. In murine models of coccidioidomycosis,
VT-1161 provided prolonged suppression of fungal burden, improved survival, and prevented dissemination of infection from
the original inoculation site to a greater extent than fluconazole
[96]. This suggests that VT-1161 might have the ability to cure
the “uncurable” syndromes such as meningitis. Efficacy has also
been demonstrated in a guinea pig model of onychomycosis
with either once-daily or weekly administration [102]. VT-1161
could be a potential treatment for mucormycosis because it has
in vitro activity against Rhizopus arrhizus var. arrhizus. This has
translated into in vivo efficacy in a mouse pulmonary infection
model, but the in vitro potency of this agent appears to be reduced against R arrhizus var. delemar [100].
VT-1129, which is structurally very similar to VT-1161, was
mainly designed to treat cryptococcal meningitis (CM). It has
potent in vitro activity against resistant Candida spp [99], and
activity is maintained against C neoformans/C gatti genotypes

Downloaded from https://academic.oup.com/ofid/article-abstract/7/2/ofaa016/5700872 by Washington University at St Louis user on 13 March 2020

Nikkomycin Z ([NikZ] developed by Valley Fever Solutions,
Inc., Tucson, AZ) is a first-in-class antifungal derived from
Streptomyces tendae, with a novel mechanism of action
through inhibition of chitin synthases, an essential component of the fungal cell wall [80] (Figure 1 and Table 1). The
target enzyme is absent in mammalian hosts, making NikZ
selective to fungal cells with little to no toxicity in humans
[80]. This agent was first described in the 1970s, but it was not
until the early 2000s that NikZ gained interest for the treatment of endemic mycoses, particularly coccidioidomycosis
[80]. This agent is under development as an orphan product
for the treatment of coccidioidomycosis, and in 2014 it gained
the QIDP designation.

AGENTS TARGETING CELL MEMBRANE

Stage of Development and Ongoing Clinical Studies

Preclinical results of VT-1129, VT-1161, and VT-1598 have
been reported in the literature, and VT-1161 is currently in
clinical development (Figure 3). Phase 2 clinical trials have
evaluated the efficacy and safety of VT-1161 for the treatment of tinea pedis, onychomycosis, and acute and recurrent VVC (NCT02267382, NCT02267356, NCT01891331,
NCT01891305) [111]. Two phase 3 trials in recruitment
(NCT03561701 and NCT03840616) will evaluate the effectiveness and safety of VT-1161 versus fluconazole and a placebo for
the treatment of VVC.
Encochleated Amphotericin B (MAT2203)

Mechanism of Action and Potential Role

MAT2203 (developed by Matinas BioPharma, Bedminster, NJ)
is a novel encochleated amphotericin B (CAmB) formulation
for oral administration [4]. Encochleated AmB, like all forms
of amphotericin, binds with sterols, leading to increased cell
membrane permeability to ions [112, 113] (Figure 1 and Table
1). Despite the highly favorable antifungal activity of AmB, the
successful treatment of IFIs remains difficult due to toxicity
in critical mammalian organ systems caused by its lack of selectivity between fungal and animal sterols [112, 113]. Recent
investigations have shown the safety and efficacy of the lipidbased cochleates formulation as a delivery system for AmB for
use in Candida infections [114]. The cochleates consist of solid
phospholipid bilayer vehicles, designed for hydrophobic drug

delivery, that are arranged in rolled-up sheets composed of divalent cation precipitates, specifically phosphatidylserine and
calcium. This structure protects the AmB encapsulated in the
cochleates molecules from degradation in the gastrointestinal
tract [114]. Cochleates result in a stable, nontoxic, highly efficacious AmB lipid particle, enabling its potential oral formulation
[112]. The drug is released upon interaction of the cochleate
with the target cells in the presence of the low intracellular calcium concentrations [4, 16]. There is direct interaction between
CAmB and the fungus cell membrane, but the precise mechanism by which cochleates fuse with cell membranes is not yet
fully understood [113]. Presumably, the drug is delivered to the
target cell cytoplasm after phagocytosis by macrophages, and
the fungal cells make contact with the lysosome and deliver the
drug content after fusion with the lysosome [4]. Its potential for
oral delivery and reduction in toxicity are the main advantages
of this drug. Encochleated AmB received QIDP designation as
well as fast track status from the FDA in 2015 for the treatment
of invasive candidiasis, aspergillosis, and the prevention of IFIs
in patients on immunosuppressive therapy. It recently received
QIDP, fast track status, and orphan drug designation for treatment of CM.
Pharmacokinetics/Pharmacodynamics

The high efficiency in vitro and in vivo can be explained by
increased uptake of the drug by fungus, which is mediated by
a direct interaction and fusion between CAmB and the fungus
cell membrane [113]. Animal models have shown extensive
tissue distribution and penetration of CAmB into target organs after administration of a single dose. The liver acts as a
reservoir, releasing AmB slowly, increasing its potential for the
treatment of IFIs [115]. In vivo, orally administered CAmB
resulted in adequate amounts of AmB reaching target organs,
including the liver, spleen, and kidneys, early in treatment.
Mice treated with CAmB had 100% survival and comparable
efficacy with that of deoxycholate AmB (DAmB), resulting in
substantial colony-forming unit count reduction in the kidneys and lungs [116]. Targeted therapy was demonstrated
after the higher AmB concentrations were seen in infected
mice, whereas no such accumulation occurred in the organs of
healthy animals [116]. Further work will be required to assess
whether immune cells are required for efficacy and concentration, because a significant portion of fungal infections occur
in neutropenic patients.
Further investigations have also shown the in vivo efficacy
of oral CAmB in a murine model of disseminated aspergillosis
[117] and activity in visceral leishmaniasis [114, 118]. Oral
CAmB has potential for treatment for CNS fungal infections, in
combination with flucytosine (5FC) in a murine model of CM
proving as effective as parenteral DAmB plus 5FC, and superior
to oral fluconazole without inconvenient toxicity after a 28-day
treatment schedule [119].
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with reduced susceptibility to fluconazole [103, 104]. Studies
have shown MIC50 that range between 0.05 and 0.25 μg/mL
for dose-dependent and -resistant Cryptococcus isolates, respectively [103, 104]. In a murine model, oral administration
of this agent resulted in improved survival and reduced tissue
fungal burden. Due to the long half-life of this agent (more
than 6 days in mice), elevated concentrations were detected in
the brain long after dosing was stopped [105]. A loading dosemaintenance dose strategy has been shown to quickly reach
highly efficacious concentrations [106]. No antagonism was observed when VT-1129 was combined with AmB [105].
Of these 3 investigational agents, VT-1598 has the broadest
spectrum and most potent activity against molds, including
various Aspergillus spp and R arrhizus, as well as endemic
fungi, including Coccidioides with elevated fluconazole MICs,
Blastomyces and Histoplasma isolates [105, 107]. A murine
model of CNS coccidioidomycosis also showed the efficacy of
VL-1598 [108]. This agent demonstrates potent in vitro and
in vivo activity against Candida species [109], including resistant isolates such as C auris (MIC range, 0.03–8 mg/L). An in
vivo study of neutropenic mice with invasive C auris infection
treated with VT-1598 resulted in significant dose-dependent
improvements in survival and reductions in kidney and brain
fungal burden compared with the control [110].

Stage of Development and Ongoing Clinical Studies

Preliminary results from a phase 1 study demonstrated that single
doses of 200 and 400 mg were well tolerated without serious AEs,
opening the way for phase 2 trials (NCT02971007) [120]. MAT2203
was well tolerated, with AEs mostly related to mild gastrointestinal
symptoms, and showed a favorable safety profile without the renal
and hepatic toxicities seen with IV AmB [121].
Enrollment is currently underway for a phase 2a clinical
trial assessing orally administered MAT2203 (200–800 mg)
in refractory mucocutaneous candidiasis (NCT02629419).
Preliminary results are promising, with MAT2203 being well
tolerated and effective [121]. A phase 1/2 trial is planned to start
recruitment in Uganda in October 2019 to evaluate CAmB for
CM (EnACT trial, NCT04031833). A phase 2 study was being
planned to investigate MAT2203 for the prevention of IFIs, but
the trial was recently withdrawn due to protocol redundancy
(NCT03187691). Matinas plans to conduct a phase 2 trial to get
MAT2203 approved for IFI prophylaxis in patients with acute
lymphoblastic leukemia [121] (Figure 3).
Aureobasidin A

Aureobasidin A ([AbA] developed by Takara Bio, Shiga, Japan)
is a cyclic depsipeptide antibiotic isolated from the filamentous
fungus Aureobasidium pullulans R106 [122, 123]. Aureobasidin
A was initially discovered in 1989, although its license patent
was granted in 2007 to AureoGen Biosciences/Merck & Co. for
further development [124].
Mechanism of Action and Potential Role

Aureobasidin A exhibits antifungal activity through inhibition of inositol phosphorylceramide synthase, an important
enzyme expressed from the AUR1 gene involved in sphingolipid synthesis, exclusively found in the fungal cell membrane [125–127] (Figure 1 and Table 1). The absence of this
enzyme in mammalian cells decreases the risk of toxicity.
Resistance to AbA can be seen due to mutation of the AUR1
gene in fungi [127].
Activity

In vitro studies have shown activity against Saccharomyces
cerevisiae, Candida spp, Cryptococcus spp, Schizosaccharomyces
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pombe, and some Aspergillus spp [122] (Figure 2). An in vivo
murine model of candidiasis showed fungicidal activity of AbA
with low toxicity and prolonged survival [123].
Stage of Development and Clinical Studies

This drug remains in the preclinical developmental, but it has a
favorable profile to advance for clinical use (Figure 3).
AGENTS WITH INTRACELLULAR TARGETS
Olorofim (F901318)

Mechanism of Action and Potential Role

Olorofim (developed by F2G, Inc., Manchester, UK) is a novel
antifungal drug in a novel class of orotomides. Its mechanism
of action involves the inhibition of fungal dihydroorotate dehydrogenase (DHODH), an important enzyme in pyrimidine
biosynthesis essential for deoxyribonucleic acid synthesis [128]
(Figure 1 and Table 1). Olorofim has no activity against human
DHODH and therefore selectively arrests fungal pyrimidine biosynthesis, resulting in limited toxicity and a favorable safety
profile [128]. There are several other appealing characteristics
of this drug including oral bioavailability and potent activity
against triazole-resistant isolates and other pan-resistant fungal
pathogens [129]. The European Medicines Agency Committee
for Orphan Medicinal Products has recently granted orphan
drug status to olorofim for the treatment of invasive aspergillosis and rare mold infections caused by Lomentospora spp.
Pharmacokinetics/Pharmacodynamics

Olorofim is relatively insoluble in water and highly protein bound [129], but it has good distribution to tissues, including kidney, liver, lung, and, although at lower levels, has
been detected in the brain [128]. Olorofim demonstrates
time-dependent killing effect [129, 130] and shows a typical
pharmacokinetic profile when dosed by IV and oral routes
(bioavailability >45%) [131]. Olorofim is cleared by multiple
CYP450 enzymes; however, it does not induce CYP450 enzymes itself. It is a weak CYP3A4 inhibitor [132], making it
prone to drug-drug interactions [16]. Olorofim has a delayed
fungicidal effect if the exposure is prolonged [130].
Activity

In vitro studies have shown broad-spectrum activity against
filamentous and dimorphic fungi including Aspergillus spp,
Histoplasma capsulatum, B dermatitidis, C immitis, Talaromyces
(formerly Penicillium) marneffei, and Fusarium spp [128], as
well as organisms pan-resistant to clinically available antifungal
agents such as Scedosporium apiospermum, L prolificans and
Scopulariopsis spp (including Scopulariopsis brumptii) [133–135].
It is highly active against all pathogenic Aspergillus spp including
wild-type and azole-resistant CYP51A mutant strains, with an
MIC of <0.1 µg/mL. It is active against cryptic species of Aspergillus
that can be hard to treat with current antifungal therapies,
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In vivo safety studies in murine models have shown 100%
survival after 30 days when administering escalating daily doses
of intraperitoneal CAmB, and equivalent safety of high oral
CAmB doses, suggesting that CAmB could be administered
in more aggressive doses (as high as 25 mg/kg) than currently
available formulas [112, 113]. Encochleated AmB produced
no hemolysis at concentrations as high as 500 µg/mL AmB,
whereas DAmB was highly hemolytic at 10 µg/mL, possibly due
to a low interaction of CAmB with red blood cells, in contrast
to DAmB [113].

Stage of Development and Ongoing Clinical Studies

Both oral and IV formulations are being developed, but the
exact dosing regimen for both formulations is still being studied.
An oral immediate release tablet evaluated in a phase 1 study
(NCT03340597) showed that olorofim was well tolerated and
effective [143]. The IV formulation was studied during clinical
development (NCT02342574 and NCT02142153) and achieved
the target steady-state plasma concentrations predicted for efficacy. Two phase 2 trials (NCT02856178 and NCT03036046) for
use as fungal prophylaxis were recently withdrawn, because they
were no longer required, and the drug is now in phase 2b clinical development with a global open-label study (FORMULAOLS, NCT03583164) to evaluate olorofim for difficult-to-treat
IFIs, including azole-resistant aspergillosis, scedosporiosis,
lomentosporiosis, and other rare molds, in patients lacking suitable alternative treatment options [144] (Figure 3).

broth of Acremonium persicinum [145]. VL-2397 is structurally
related to the siderophore ferrichrome, a low molecular weight
siderophore with high specificity for iron. This agent is able to
chelate aluminum ions instead of iron; however, its exact mechanism of action is not fully understood, because the aluminum
compound does not inhibit fungal growth [146]. Activity results from its effect on an unknown intracellular target (Figure
1 and Table 1). However, it is known that it triggers a potent
and rapid antifungal effect after transport into fungal cells, specifically A fumigatus, via siderophore iron transporter 1 (Sit1),
which is absent in mammalian cells. Live cell imaging suggests
that VL-2397 causes arrest of hyphal elongation [147]. The FDA
has granted QIDP, Orphan Drug, and fast track designations to
VL-2397 for the treatment of invasive aspergillosis.
Activity

VL-2397 is active against different fungi (Figure 2). It demonstrates rapid onset of inhibition (within the first 2 to 4 hours)
and potent in vitro fungicidal activity against hyphal elongation
compared with existing drugs [147, 148]. It has proven activity
against Aspergillus spp (including wild-type as well as azoleresistant strains), some Candida spp (only C glabrata and C
kefyr), C neoformans, and Trichosporon asahii. The agent appears
to have limited activity against Fusarium solani, and it is not active against A niger, Mucorales, Scedosporium apiospermum, and
Fonsecaea pedrosoi [148]. This has translated into in vivo efficacy
in a silkworm model and neutropenic murine models of invasive
pulmonary aspergillosis, where VL-2397 caused dose-dependent
prolongation of survival and reduction in fungal burden in the
lung [145]. There is evidence of in vivo efficacy in a neutropenic
murine model of invasive candidiasis caused by both wild-type
and azole- and echinocandin-resistant C glabrata isolates [149].
Stage of Development and Ongoing Clinical Studies

A phase 1 study showed that this agent was well tolerated in
healthy volunteers who received escalating single and multiple IV doses per day [150]. It was well tolerated up to 1200
mg, and no accumulation was observed for 21 days [150, 151].
There were no reported serious AEs related to the drug [150,
151]. VL-2397 demonstrated nonlinear saturable binding kinetics, most likely due to protein binding [148]. A phase 2 trial
(NCT03327727) for the treatment of invasive aspergillosis in
acute leukemia patients and recipients of bone marrow transplants was underway, but this was terminated early due to a
business decision [152]. It is unfortunate that there are no ongoing trials at this time (Figure 3).

VL-2397

T-2307

Mechanism of Action and Potential Role

Mechanism of Action and Potential Role

VL-2397 (formerly ASP2397, developed by Vical
Pharmaceuticals) potentially represents a new class of antifungal
agents. It is a cyclic hexapeptide isolated from the fermentation

T-2307 (synthesized at Toyama Chemical Co., Llt., Tokyo,
Japan) is an investigational arylamidine, structurally similar to
a class of aromatic diamidines that includes pentamidine [153].
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such as Aspergillus nidulans, Aspergillus tubingensis, Aspergillus
lentulus, and Aspergillus calidoustus, with lower MICs than AmB,
voriconazole, and posaconazole [129, 136, 137]. This agent displays potent in vitro activity against most molds with a limited
variation in EUCAST susceptibility testing [138]. Organisms that
remain susceptible to olorofim are grouped together under the
same DHODH phylogenetic tree, whereas the lack of activity seen
against Candida spp, C neoformans, and Mucorales is due to a distantly related DHODH [128]. Resistance to olorofim, as assessed
by serial passage and drug gradients, does not appear to be easily
induced, at least with A fumigatus [128]. Lack of cross-resistance
was also demonstrated with azole-resistant Aspergillus spp mutant
strains [139] (Figure 2).
Olorofim demonstrated in vivo efficacy in murine models of
invasive aspergillosis caused by wild-type and azole-resistant
strains [128, 129, 140]. Olorofim was also highly efficacious
in prolonging survival of mice with disseminated aspergillosis [128, 129, 140]. In vivo efficacy with up to 88% survival of
intraperitoneal olorofim dosing (15 mg/kg 3 times daily) was recently reported against infection with A fumigatus, A nidulans,
and Aspergillus tanneri in both neutropenic and chronic granulomatous disease mouse models of invasive aspergillosis [141].
Olorofim therapy demonstrated robust antifungal activity,
leading to prolonged survival and a concentration-dependent
decline in circulating galactomannan levels in an immunosuppressed murine model of acute sinopulmonary infection caused
by 4 clinical A flavus isolates (MIC ranged from 0.015 to 0.06
mg/L), which correlated with histological clearance of lung
tissue [142].

Activity

T-2307 has potent in vitro and in vivo activity against Candida
species, including azole- and echinocandin-resistant Candida
spp, C neoformans, C gattii, Malassezia furfur, and F solani
[157–161]. The in vitro activity of T-2307 was far superior to
the activities of fluconazole, voriconazole, micafungin, and
AmB. T-2307 was active against Aspergillus spp, and in vitro activity against these species was shown to be comparable to the
activities of micafungin and voriconazole [157] (Figure 2).
Stage of Development and Ongoing Clinical Studies

For this potential antifungal drug, phase 1 studies are still ongoing, and no clinical efficacy data are available (Figure 3).
AR-12

Mechanism of Action

AR-12 (developed by Arno Therapeutics Inc., Flemington, NJ)
is a novel molecule, antitumor celecoxib-derivative that has progressed to clinical development as an anticancer agent and has
activity against a number of infectious agents including fungi,
bacteria, and viruses [162]. With the goal of repurposing, a set of
anticancer protein kinase inhibitors were screened for molecules
with fungicidal activity towards C neoformans and C albicans, and
AR-12 was found to have good antifungal activity against both
species [163]. This agent acts by 2 different mechanisms of action,
first by inhibiting the activity of fungal acetyl-CoA synthetase
[164], and by downregulating host chaperone proteins, increasing
the host immune response [16, 17] (Figure 1 and Table 1). It is
interesting to note that AR-12 has also shown activity against bacteria, including Salmonella and Francisella, and hemorrhagic fever
viruses [162]. The European Commission has designated AR-12
as an orphan drug for use in combination with other drugs for
treatment of cryptococcosis and tularemia.
Activity

AR-12 has broad-spectrum antifungal activity against
yeasts, molds, and dimorphic fungi (Figure 2). This includes
Candida spp, including C glabrata and C krusei, and isolates
of C neoformans with elevated fluconazole MICs [164]. It
has also shown activity against dimorphic fungi including
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Blastomyces, Histoplasma, and Coccidioides [164]. In a murine model of cryptococcosis, AR-12 was synergistic with
fluconazole [165]. However, the most promising feature of
AR-12 is its in vitro activity against difficult-to-treat molds,
including Fusarium, Mucor, and Scedosporium [164]. In a
recent study, AR-12 was found to be highly active against
Trichophyton rubrum, one of the organisms predominantly
responsible for onychomycosis [166].
Stage of Development and Ongoing Clinical Studies

Target serum concentrations providing antifungal activity were
safely achieved during phase 1 clinical trials as an anticancer
agent (NCT00978523), indicating that AR-12 is promising candidate for repurposing as an antifungal agent [162]. However,
Arno Therapeutics declared bankruptcy in 2017 leaving the future of the medication in limbo (Figure 3).
MGCD290

Mechanism of Action and Potential Role

MGCD290 (developed by MethylGene, Inc., Montreal, Canada)
is a novel antifungal that inhibits fungal histone deacetylase 2 [16,
17]. Histone deacetylase is an enzyme that removes lysine residues
of core histones, which control gene transcription and expression
(Figure 1 and Table 1). They also control nonhistone proteins, including Hsp90, a molecular chaperone that regulates cellular stress
response. In fungal cells, Hsp90 has been shown to be responsible for morphogenetic changes, stress adaptation, virulence, and
antifungal resistance [167]. MGCD290 has shown a synergistic
effect with other antifungals such as azoles or echinocandins [17,
167]. In cases of mutant-resistant isolates, MGCD290 produces a
favorable influence on the MICs, restoring sensitivity [168].
Activity

MGCD290 only has modest activity against Candida spp [168].
However, it has demonstrated in vitro synergy with azoles and
echinocandins against many azole- and echinocandin-resistant
isolates including Candida spp, Aspergillus spp, Mucor, and
Fusarium [168, 169] (Figure 2).
Stage of Development and Clinical Studies

This drug is currently in clinical development, and a phase 2
trial (NCT01497223) was completed that evaluated the cure
rate with combination treatment of MGCD290 and fluconazole
compared with fluconazole alone for patients with moderate to
severe VVC [170] (Figure 3). This yielded poor results with no
statistically significant benefit of combination therapy [171].
DEVICE
Neurapheresis

Mechanism of Action and Potential Role

The neurapheresis therapy system (developed by Minnetronix,
Inc., St. Paul, MN) is a closed-loop system designed to filter
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Its mechanism of action remains unknown; however, it appears
to cause the collapse of fungal mitochondrial membrane potential in yeasts [154] (Figure 1 and Table 1). T-2307 is preferentially taken up by fungal cells via high-affinity spermine and
spermidine transport systems with evidence of little effect on
rat liver mitochondrial function [153, 155]. This transportermediated uptake contributes to its activity against Candida and
makes it clinically safer than pentamidine. T-2307 inhibits the
respiratory chain complexes in whole yeast cells and isolated
yeast mitochondria, which is key for selective disruption of
yeast mitochondrial function and antifungal activity [156].

fungal pathogens from human cerebrospinal fluid (CSF) (Table
1). It operates by extracting CSF from the subarachnoid space,
removing pathogens through a filtration system, and then redepositing the CSF through the same catheter [172]. It is currently considered as a potential novel adjunctive therapy for
CM.

Smilnak et al [172] demonstrated the effects both in vitro
and in vivo. Filtration of C neoformans in vitro accomplished a 5-log reduction in yeasts over 24 hours, compared
with AmB plus 5FC, which achieved 0.42-log clearance of
colony-forming units of yeast/mL per day from CSF [173].
Another in vivo rabbit model demonstrated a large decrease
(97%) in yeast concentration after 4–6 hours of filtration.
Concentrations of cryptococcal antigen decreased substantially (≥90%) postfiltration. Removal of cryptococcal antigen, which is responsible for occluding arachnoid villi, as
well as rapid clearing of both single and clumping yeasts
from the CSF, may reverse outflow obstruction in CM patients and alleviate resulting headaches and hydrocephaly.
The neurapheresis system is expected to (1) allow physicians to modulate the high ICP typical of CM patients
more directly and (2) also serve as a favorable alternative
to other drainage procedures, minimizing the need for repeated lumbar punctures and/or placement of shunts [172].
The system was first used in a patient with subarachnoid
hemorrhage, for which she underwent lumbar catheter
placement and completed 9 hours of CSF filtration without
complications. Repeat imaging demonstrated interval reduction of subarachnoid hemorrhage immediately after filtration [174]. In addition, it was piloted as treatment for
other conditions such as bacterial meningitis and leptomeningeal disease [175, 176]. The ability of neurapheresis
to reduce C neoformans and cryptococcal antigen demonstrates its potential to efficiently treat CM as an adjunctive therapy to systemic antifungals. Given its utility and
the ability to directly remove the pathogen and secondary
virulence factors, this platform is an appealing choice for
adjunctive treatment of other fungal meningitis, such as the
coccidioidal meningitis [172].
Ongoing studies include a clinical trial (PILLAR trial,
NCT02872636) evaluating the safety and feasibility of this
system in patients with subarachnoid hemorrhages. Another
study testing the potential of neurapheresis therapy to reduce
fungal burden in human patients with CM is currently being
planned. Upcoming studies will explore the ability of the
neurapheresis system to (1) filter smaller mediators such as
cytokines and chemokines to control the neuroinflammatory
response seen in CM and (2) avoid dangerous levels of inflammation or even immune reconstitution inflammatory syndrome
(IRIS) within the CNS [172].

Despite a large number of patients suffering, the global burden
of IFIs remains relatively underappreciated and underfunded.
We face many challenges in the treatment of these diseases due
to increasing resistance to currently available antifungals, demanding the need for development of new treatment options.
This review focused on several novel antifungal therapies at
various clinical stages in the development pipeline, including a
first device used as adjunctive therapy.
These new antifungals have many potential roles and advantages over current drugs. New drugs, including olorofim,
fosmanogepix, and ibrexafungerp, are now available options
for the treatment of previously pan-resistant organisms. This
is incredibly important because these drugs offer options for
physicians where there were previously no treatment avenues
available. In the case of olorofim, physicians now have another
course of action in tackling triazole-resistant Aspergillus isolates [129] and other pan-resistant fungal pathogens including
Lomentospora spp [133]. Still, chemical classes for IFI treatment
are so few that emergence of resistance to even 1 drug class tragically limits therapy options.
Many of the described therapies have improved safety profiles with reduced toxicity and fewer adverse effects and drugdrug interactions while preserving efficacy. A majority of IFI
cases are seen in patients with other comorbid conditions [177],
and a variety of treatments and procedures for other conditions
are well recognized risk factors for developing IFIs, such as abdominal surgery, chemotherapy, and use central venous catheters. With these patients being treated for multiple reasons
concurrently, drug-drug interactions and compound toxicities
are significant concerns for physicians. A patient’s ability to
tolerate the effects of treatment can limit a clinician when prescribing a course of treatment, especially in critically ill patients.
For example, CAmB minimizes the toxicity seen with AmB by
using cochleates as a drug delivery system to target the fungal
cell membrane. Likewise, olorofim and fosmanogepix have
lower risk of toxicity due to fungal-specific targets, and they
also possess novel mechanisms of action by inhibition of fungal
DHODH for pyrimidine synthesis and Gwt1 for GPI-anchor
protein synthesis, respectively. The caveat of olorofim is related
to possible drug-drug interactions given its weak inhibition of
CYP3A4. Drug-drug interactions are minimized while using
CamB and also with tetrazoles because they selectively target
the fungal CYP51 enzyme.
The burden of administration requirements is reduced with
the oral formulation of ibrexafungerp, olorofim, and CAmB
decreasing barriers of IV administration, and rezafungin has a
longer half-life allowing weekly dosing. Complex dosing schedules and IV administration requirements are known to negatively impact medication adherence [178, 179], and, for patients
receiving antifungal treatment for extended periods, these oral
formulations and reduced dosing intervals have the potential to
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decrease hospital and clinic visits and ultimately increase patient adherence during treatment.
CONCLUSIONS
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